Vancomycin
Ulcerative Colitis (UC)
Tampere University HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Ulcerative Colitis (UC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxygen Jay C. Buckey Jr. | Phase 4 | BB |
Mmx Mesalamine/Mesalazine Shire | Phase 3 | B |
Hextend Corewell Health West | Phase 3 | B |
Mesalamine Shire | Phase 3 | B |
Gralise Shirley Ryan AbilityLab | Phase 4 | B |
View all 30 →
Same molecule, other indications
Vancomycin is also rated in:
methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
68 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →